;PMID: 7858891
;source_file_830.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..38] = [t:0..38]
;1)sentence:[e:44..123] = [t:44..123]
;2)section:[e:127..158] = [t:127..158]
;3)section:[e:162..231] = [t:162..231]
;4)sentence:[e:235..237] = [t:235..237]
;5)sentence:[e:238..530] = [t:238..530]
;6)sentence:[e:531..533] = [t:531..533]
;7)sentence:[e:534..837] = [t:534..837]
;8)sentence:[e:838..840] = [t:838..840]
;9)sentence:[e:841..1073] = [t:841..1073]
;10)sentence:[e:1075..1077] = [t:1075..1077]
;11)sentence:[e:1078..1237] = [t:1078..1237]
;12)sentence:[e:1239..1241] = [t:1239..1241]
;13)sentence:[e:1242..1395] = [t:1242..1395]
;14)sentence:[e:1397..1399] = [t:1397..1399]
;15)sentence:[e:1400..1514] = [t:1400..1514]
;16)sentence:[e:1515..1517] = [t:null]
;17)sentence:[e:1518..1656] = [t:1518..1656]
;18)sentence:[e:1657..1659] = [t:1657..1659]
;19)sentence:[e:1660..1781] = [t:1660..1781]
;20)section:[e:1785..1829] = [t:1785..1829]
;Sentence Matching Errors
;ERROR_Different number of sections entity has 21 tree 20
;ERROR_Entity section missing treebank section[1515..1517]
;Token/POS Errors
;ERROR_Token in entity file but not tree[482..487] cyclo
;ERROR_Token in entity file but not tree[1515..1517] 7.
;ERROR_Token in tree file but not entity[481..487]  cyclo

;section 0 Span:0..38
;Br J Pharmacol. 1994 Nov;113(3):954-8.
(SEC
  (FRAG (NNP:[0..2] Br) (NNP:[3..4] J) (NNP:[5..14] Pharmacol) (.:[14..15] .)
        (CD:[16..20] 1994) (CC:[21..29] Nov;113-LRB-) (CD:[29..30] 3)
        (-RRB-:[30..31] -RRB-) (CD:[31..35] :954) (HYPH:[35..36] -)
        (CD:[36..38] 8.)))

;sentence 1 Span:44..123
;Role of K+ channels in the vasodilator response to bradykinin in the rat
;heart.
;[52..54]:substance:"K+"
;[71..82]:substance:"vasodilator"
;[95..105]:substance:"bradykinin"
(SENT
  (NP-HLN
    (NP (NN:[44..48] Role))
    (PP (IN:[49..51] of)
      (NP
        (NML (NN:[52..53] K) (SYM:[53..54] +))
        (NNS:[55..63] channels)))
    (PP (IN:[64..66] in)
      (NP
        (NP (DT:[67..70] the) (JJ:[71..82] vasodilator) (NN:[83..91] response))
        (PP (TO:[92..94] to)
          (NP (NN:[95..105] bradykinin)))))
    (PP-LOC (IN:[106..108] in)
      (NP (DT:[109..112] the) (NN:[113..116] rat) (NN:[117..122] heart)))
    (.:[122..123] .)))

;section 2 Span:127..158
;Fulton D, McGiff JC, Quilley J.
(SEC
  (FRAG (NNP:[127..133] Fulton) (NNP:[134..135] D) (,:[135..136] ,)
        (NNP:[137..143] McGiff) (NNP:[144..146] JC) (,:[146..147] ,)
        (NNP:[148..155] Quilley) (NNP:[156..158] J.)))

;section 3 Span:162..231
;Department of Pharmacology, New York Medical College, Valhalla 10595.
(SEC
  (FRAG (NNP:[162..172] Department) (IN:[173..175] of)
        (NNP:[176..188] Pharmacology) (,:[188..189] ,) (NNP:[190..193] New)
        (NNP:[194..198] York) (NNP:[199..206] Medical) (NNP:[207..214] College)
        (,:[214..215] ,) (NNP:[216..224] Valhalla) (CD:[225..230] 10595)
        (.:[230..231] .)))

;sentence 4 Span:235..237
;1.
(SENT
  (NP (LS:[235..237] 1.)))

;sentence 5 Span:238..530
;The role of K+ channels in the nitric oxide (NO)-independent coronary 
;vasodilator effect of bradykinin was examined in the Langendorff heart 
;preparation in which nitroarginine was used to inhibit NO synthesis and
;elevate  perfusion pressure; cyclo-oxygenase was inhibited with
;indomethacin.
;[250..252]:substance:"K+"
;[269..281]:substance:"nitric oxide"
;[283..285]:substance:"NO"
;[309..320]:substance:"vasodilator"
;[331..341]:substance:"bradykinin"
;[402..415]:substance:"nitroarginine"
;[436..438]:substance:"NO"
;[482..497]:substance:"cyclo-oxygenase"
;[517..529]:substance:"indomethacin"
(SENT
  (S
    (S
      (NP-SBJ-4
        (NP (DT:[238..241] The) (NN:[242..246] role))
        (PP (IN:[247..249] of)
          (NP
            (NML (NN:[250..251] K) (SYM:[251..252] +))
            (NNS:[253..261] channels)))
        (PP (IN:[262..264] in)
          (NP
            (NP (DT:[265..268] the)
              (ADJP
                (NML
                  (NML (JJ:[269..275] nitric) (NN:[276..281] oxide))
                  (NML (-LRB-:[282..283] -LRB-) (NN:[283..285] NO)
                       (-RRB-:[285..286] -RRB-)))
                (HYPH:[286..287] -) (JJ:[287..298] independent))
              (JJ:[299..307] coronary) (NN:[309..320] vasodilator)
               (NN:[321..327] effect))
            (PP (IN:[328..330] of)
              (NP (NN:[331..341] bradykinin))))))
      (VP (VBD:[342..345] was)
        (VP (VBN:[346..354] examined)
          (NP-4 (-NONE-:[354..354] *))
          (PP (IN:[355..357] in)
            (NP
              (NP (DT:[358..361] the) (NNP:[362..373] Langendorff)
                  (NN:[374..379] heart) (NN:[381..392] preparation))
              (SBAR
                (WHPP-2 (IN:[393..395] in)
                  (WHNP (DT:[396..401] which)))
                (S
                  (NP-SBJ-3 (NN:[402..415] nitroarginine))
                  (VP (VBD:[416..419] was)
                    (VP (VBN:[420..424] used)
                      (NP-3 (-NONE-:[424..424] *))
                      (S-PRP
                        (NP-SBJ (-NONE-:[424..424] *))
                        (VP (TO:[425..427] to)
                          (VP
                            (VP (VB:[428..435] inhibit)
                              (NP (NN:[436..438] NO) (NN:[439..448] synthesis)))
                            (CC:[449..452] and)
                            (VP (VB:[453..460] elevate)
                              (NP (NN:[462..471] perfusion)
                                  (NN:[472..480] pressure))))))
                      (PP-2 (-NONE-:[480..480] *T*)))))))))))
    (::[480..481] ;)
    (S
      (NP-SBJ-1 (AFX:[481..487] cyclo) (HYPH:[487..488] -)
                (NN:[488..497] oxygenase))
      (VP (VBD:[498..501] was)
        (VP (VBN:[502..511] inhibited)
          (NP-1 (-NONE-:[511..511] *))
          (PP-MNR (IN:[512..516] with)
            (NP (NN:[517..529] indomethacin))))))
    (.:[529..530] .)))

;sentence 6 Span:531..533
;2.
(SENT
  (NP (LS:[531..533] 2.)))

;sentence 7 Span:534..837
;The K+  channel inhibitors, tetraethylammonium, procaine and charybdotoxin,
;but not  glibenclamide, further increased perfusion pressure suggesting a
;role for K+  channels, other than ATP-sensitive K+ channels, in the
;regulation of coronary  vascular tone under the experimental conditions
;adopted here.
;[538..540]:substance:"K+"
;[550..560]:substance:"inhibitors"
;[562..580]:substance:"tetraethylammonium"
;[582..590]:substance:"procaine"
;[595..608]:substance:"charybdotoxin"
;[619..632]:substance:"glibenclamide"
;[693..695]:substance:"K+"
;[718..721]:substance:"ATP"
;[732..734]:substance:"K+"
(SENT
  (S
    (NP-SBJ
      (NP (DT:[534..537] The)
        (NML
          (NML (NN:[538..539] K) (SYM:[539..540] +))
          (NN:[542..549] channel))
        (NNS:[550..560] inhibitors))
      (,:[560..561] ,)
      (NP (NN:[562..580] tetraethylammonium) (,:[580..581] ,)
          (NN:[582..590] procaine) (CC:[591..594] and)
          (NN:[595..608] charybdotoxin) (,:[608..609] ,)
        (CONJP (CC:[610..613] but) (RB:[614..617] not))
        (NN:[619..632] glibenclamide)))
    (,:[632..633] ,)
    (ADVP (RB:[634..641] further))
    (VP (VBD:[642..651] increased)
      (NP (NN:[652..661] perfusion) (NN:[662..670] pressure))
      (S-ADV
        (NP-SBJ (-NONE-:[670..670] *))
        (VP (VBG:[671..681] suggesting)
          (NP
            (NP (DT:[682..683] a) (NN:[684..688] role))
            (PP (IN:[689..692] for)
              (NP
                (NP
                  (NML (NN:[693..694] K) (SYM:[694..695] +))
                  (NNS:[697..705] channels))
                (,:[705..706] ,)
                (ADJP (JJ:[707..712] other)
                  (PP (IN:[713..717] than)
                    (NP
                      (ADJP (NN:[718..721] ATP) (HYPH:[721..722] -)
                            (JJ:[722..731] sensitive))
                      (NML (NN:[732..733] K) (SYM:[733..734] +))
                      (NNS:[735..743] channels))))))
            (,:[743..744] ,)
            (PP (IN:[745..747] in)
              (NP
                (NP (DT:[748..751] the) (NN:[752..762] regulation))
                (PP (IN:[763..765] of)
                  (NP (JJ:[766..774] coronary) (JJ:[776..784] vascular)
                      (NN:[785..789] tone)))
                (PP (IN:[790..795] under)
                  (NP
                    (NP (DT:[796..799] the) (JJ:[800..812] experimental)
                        (NNS:[813..823] conditions))
                    (VP (VBN:[824..831] adopted)
                      (NP (-NONE-:[831..831] *))
                      (ADVP (RB:[832..836] here)))))))))))
    (.:[836..837] .)))

;sentence 8 Span:838..840
;3.
(SENT
  (NP (LS:[838..840] 3.)))

;sentence 9 Span:841..1073
;The  non-specific K+ channel inhibitors, tetraethylammonium and procaine,
;reduced  vasodilator responses to bradykinin and cromakalim but not those to 
;nitroprusside in the perfused heart treated with nitroarginine and
;indomethacin.
;[859..861]:substance:"K+"
;[870..880]:substance:"inhibitors"
;[882..900]:substance:"tetraethylammonium"
;[905..913]:substance:"procaine"
;[924..935]:substance:"vasodilator"
;[949..959]:substance:"bradykinin"
;[964..974]:substance:"cromakalim"
;[993..1006]:substance:"nitroprusside"
;[1042..1055]:substance:"nitroarginine"
;[1060..1072]:substance:"indomethacin"
(SENT
  (S
    (NP-SBJ
      (NP (DT:[841..844] The)
        (ADJP (AFX:[846..849] non) (HYPH:[849..850] -) (JJ:[850..858] specific))
        (NML
          (NML (NN:[859..860] K) (SYM:[860..861] +))
          (NN:[862..869] channel))
        (NNS:[870..880] inhibitors))
      (,:[880..881] ,)
      (NP (NN:[882..900] tetraethylammonium) (CC:[901..904] and)
          (NN:[905..913] procaine)))
    (,:[913..914] ,)
    (VP
      (VP (VBD:[915..922] reduced)
        (NP=1
          (NP (NN:[924..935] vasodilator) (NNS:[936..945] responses))
          (PP (TO:[946..948] to)
            (NP (NN:[949..959] bradykinin) (CC:[960..963] and)
                (NN:[964..974] cromakalim)))))
      (CC:[975..978] but)
      (VP (RB:[979..982] not)
        (NP=1
          (NP (DT:[983..988] those))
          (PP (TO:[989..991] to)
            (NP (NN:[993..1006] nitroprusside)))))
      (PP-LOC (IN:[1007..1009] in)
        (NP
          (NP (DT:[1010..1013] the) (VBN:[1014..1022] perfused)
              (NN:[1023..1028] heart))
          (VP (VBN:[1029..1036] treated)
            (NP (-NONE-:[1036..1036] *))
            (PP-MNR (IN:[1037..1041] with)
              (NP (NN:[1042..1055] nitroarginine) (CC:[1056..1059] and)
                  (NN:[1060..1072] indomethacin)))))))
    (.:[1072..1073] .)))

;sentence 10 Span:1075..1077
;4.
(SENT
  (NP (LS:[1075..1077] 4.)))

;sentence 11 Span:1078..1237
;Glibenclamide, an inhibitor of ATP-sensitive K+ channels, reduced vasodilator
; responses to cromakalim but did not affect those to bradykinin or
;nitroprusside.
;[1078..1091]:substance:"Glibenclamide"
;[1096..1105]:substance:"inhibitor"
;[1109..1112]:substance:"ATP"
;[1123..1125]:substance:"K+"
;[1144..1155]:substance:"vasodilator"
;[1170..1180]:substance:"cromakalim"
;[1209..1219]:substance:"bradykinin"
;[1223..1236]:substance:"nitroprusside"
(SENT
  (S
    (NP-SBJ
      (NP (NN:[1078..1091] Glibenclamide))
      (,:[1091..1092] ,)
      (NP
        (NP (DT:[1093..1095] an) (NN:[1096..1105] inhibitor))
        (PP (IN:[1106..1108] of)
          (NP
            (ADJP (NN:[1109..1112] ATP) (HYPH:[1112..1113] -)
                  (JJ:[1113..1122] sensitive))
            (NML (NN:[1123..1124] K) (SYM:[1124..1125] +))
            (NNS:[1126..1134] channels)))))
    (,:[1134..1135] ,)
    (VP
      (VP (VBD:[1136..1143] reduced)
        (NP
          (NP (NN:[1144..1155] vasodilator) (NNS:[1157..1166] responses))
          (PP (TO:[1167..1169] to)
            (NP (NN:[1170..1180] cromakalim)))))
      (CC:[1181..1184] but)
      (VP (VBD:[1185..1188] did) (RB:[1189..1192] not)
        (VP (VB:[1193..1199] affect)
          (NP
            (NP (DT:[1200..1205] those))
            (PP (TO:[1206..1208] to)
              (NP (NN:[1209..1219] bradykinin) (CC:[1220..1222] or)
                  (NN:[1223..1236] nitroprusside)))))))
    (.:[1236..1237] .)))

;sentence 12 Span:1239..1241
;5.
(SENT
  (NP (LS:[1239..1241] 5.)))

;sentence 13 Span:1242..1395
;Charybdotoxin, an antagonist of Ca(2+)-activated K+ channels, inhibited 
;responses to bradykinin but did not affect those to cromakalim or
;nitroprusside.
;[1242..1255]:substance:"Charybdotoxin"
;[1260..1270]:substance:"antagonist"
;[1274..1280]:substance:"Ca(2+)"
;[1291..1293]:substance:"K+"
;[1328..1338]:substance:"bradykinin"
;[1367..1377]:substance:"cromakalim"
;[1381..1394]:substance:"nitroprusside"
(SENT
  (S
    (NP-SBJ
      (NP (NN:[1242..1255] Charybdotoxin))
      (,:[1255..1256] ,)
      (NP
        (NP (DT:[1257..1259] an) (NN:[1260..1270] antagonist))
        (PP (IN:[1271..1273] of)
          (NP
            (ADJP (NN:[1274..1280] Ca-LRB-2+-RRB-) (HYPH:[1280..1281] -)
                  (VBN:[1281..1290] activated))
            (NML (NN:[1291..1292] K) (SYM:[1292..1293] +))
            (NNS:[1294..1302] channels)))))
    (,:[1302..1303] ,)
    (VP
      (VP (VBD:[1304..1313] inhibited)
        (NP
          (NP (NNS:[1315..1324] responses))
          (PP (TO:[1325..1327] to)
            (NP (NN:[1328..1338] bradykinin)))))
      (CC:[1339..1342] but)
      (VP (VBD:[1343..1346] did) (RB:[1347..1350] not)
        (VP (VB:[1351..1357] affect)
          (NP
            (NP (DT:[1358..1363] those))
            (PP (TO:[1364..1366] to)
              (NP (NN:[1367..1377] cromakalim) (CC:[1378..1380] or)
                  (NN:[1381..1394] nitroprusside)))))))
    (.:[1394..1395] .)))

;sentence 14 Span:1397..1399
;6.
(SENT
  (NP (LS:[1397..1399] 6.)))

;sentence 15 Span:1400..1514
;Nifedipine inhibited vasodilator responses to bradykinin and cromakalim 
;without affecting those to nitroprusside.
;[1400..1410]:substance:"Nifedipine"
;[1421..1432]:substance:"vasodilator"
;[1446..1456]:substance:"bradykinin"
;[1461..1471]:substance:"cromakalim"
;[1500..1513]:substance:"nitroprusside"
(SENT
  (S
    (NP-SBJ (NN:[1400..1410] Nifedipine))
    (VP (VBD:[1411..1420] inhibited)
      (NP
        (NP (NN:[1421..1432] vasodilator) (NNS:[1433..1442] responses))
        (PP (TO:[1443..1445] to)
          (NP (NN:[1446..1456] bradykinin) (CC:[1457..1460] and)
              (NN:[1461..1471] cromakalim))))
      (PP (IN:[1473..1480] without)
        (S-NOM
          (NP-SBJ (-NONE-:[1480..1480] *))
          (VP (VBG:[1481..1490] affecting)
            (NP
              (NP (DT:[1491..1496] those))
              (PP (TO:[1497..1499] to)
                (NP (NN:[1500..1513] nitroprusside))))))))
    (.:[1513..1514] .)))

(ORPH 7.)

;sentence 16 Span:1518..1656
;Inhibition of cytochrome P450 with  clotrimazole reduced responses to
;bradykinin but did not modify those to  cromakalim or nitroprusside.
;[1532..1547]:cyp450:"cytochrome P450"
;[1554..1566]:substance:"clotrimazole"
;[1588..1598]:substance:"bradykinin"
;[1628..1638]:substance:"cromakalim"
;[1642..1655]:substance:"nitroprusside"
(SENT
  (S
    (NP-SBJ
      (NP (NN:[1518..1528] Inhibition))
      (PP (IN:[1529..1531] of)
        (NP (NN:[1532..1542] cytochrome) (NN:[1543..1547] P450)))
      (PP (IN:[1548..1552] with)
        (NP (NN:[1554..1566] clotrimazole))))
    (VP
      (VP (VBD:[1567..1574] reduced)
        (NP
          (NP (NNS:[1575..1584] responses))
          (PP (TO:[1585..1587] to)
            (NP (NN:[1588..1598] bradykinin)))))
      (CC:[1599..1602] but)
      (VP (VBD:[1603..1606] did) (RB:[1607..1610] not)
        (VP (VB:[1611..1617] modify)
          (NP
            (NP (DT:[1618..1623] those))
            (PP (TO:[1624..1626] to)
              (NP (NN:[1628..1638] cromakalim) (CC:[1639..1641] or)
                  (NN:[1642..1655] nitroprusside)))))))
    (.:[1655..1656] .)))
;ERROR_Orphan Text from Tree File[1514..1518] 7.

;sentence 17 Span:1657..1659
;8.
(SENT
  (NP (LS:[1657..1659] 8.)))

;sentence 18 Span:1660..1781
;These results suggest that bradykinin utilizes a  Ca(2+)-activated K+ channel
;to produce vasodilatation in the rat heart.
;[1687..1697]:substance:"bradykinin"
;[1710..1716]:substance:"Ca(2+)"
;[1727..1729]:substance:"K+"
(SENT
  (S
    (NP-SBJ (DT:[1660..1665] These) (NNS:[1666..1673] results))
    (VP (VBP:[1674..1681] suggest)
      (SBAR (IN:[1682..1686] that)
        (S
          (NP-SBJ (NN:[1687..1697] bradykinin))
          (VP (VBZ:[1698..1706] utilizes)
            (NP (DT:[1707..1708] a)
              (ADJP (NN:[1710..1716] Ca-LRB-2+-RRB-) (HYPH:[1716..1717] -)
                    (VBN:[1717..1726] activated))
              (NML (NN:[1727..1728] K) (SYM:[1728..1729] +))
              (NN:[1730..1737] channel))
            (S-PRP
              (NP-SBJ (-NONE-:[1737..1737] *))
              (VP (TO:[1738..1740] to)
                (VP (VB:[1741..1748] produce)
                  (NP (NN:[1749..1763] vasodilatation))
                  (PP-LOC (IN:[1764..1766] in)
                    (NP (DT:[1767..1770] the) (NN:[1771..1774] rat)
                        (NN:[1775..1780] heart))))))))))
    (.:[1780..1781] .)))

;section 19 Span:1785..1829
;PMID: 7858891 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[1785..1789] PMID) (::[1789..1790] :) (CD:[1791..1798] 7858891)
        (-LRB-:[1799..1800] -LSB-) (NNP:[1800..1806] PubMed)
        (HYPH:[1807..1808] -) (NN:[1809..1816] indexed) (IN:[1817..1820] for)
        (NNP:[1821..1828] MEDLINE) (-RRB-:[1828..1829] -RSB-)))
